company background image
MRUS

Merus NasdaqGM:MRUS Stock Report

Last Price

US$22.08

Market Cap

US$961.6m

7D

11.1%

1Y

-1.6%

Updated

26 Jun, 2022

Data

Company Financials +
MRUS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

MRUS Stock Overview

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands.

Merus Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Merus
Historical stock prices
Current Share PriceUS$22.08
52 Week HighUS$33.09
52 Week LowUS$13.47
Beta1.12
1 Month Change57.94%
3 Month Change-18.13%
1 Year Change-1.65%
3 Year Change50.72%
5 Year Change39.31%
Change since IPO119.92%

Recent News & Updates

May 14
Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

Celebrations may be in order for Merus N.V. ( NASDAQ:MRUS ) shareholders, with the analysts delivering a significant...

Apr 25
Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

MRUSUS BiotechsUS Market
7D11.1%10.3%6.6%
1Y-1.6%-24.3%-18.4%

Return vs Industry: MRUS exceeded the US Biotechs industry which returned -24.4% over the past year.

Return vs Market: MRUS exceeded the US Market which returned -18.5% over the past year.

Price Volatility

Is MRUS's price volatile compared to industry and market?
MRUS volatility
MRUS Average Weekly Movement13.7%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: MRUS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: MRUS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2003117Bill Lundberghttps://www.merus.nl

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.

Merus Fundamentals Summary

How do Merus's earnings and revenue compare to its market cap?
MRUS fundamental statistics
Market CapUS$961.59m
Earnings (TTM)-US$75.55m
Revenue (TTM)US$52.41m

18.3x

P/S Ratio

-12.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MRUS income statement (TTM)
RevenueUS$52.41m
Cost of RevenueUS$104.36m
Gross Profit-US$51.94m
Other ExpensesUS$23.61m
Earnings-US$75.55m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.73
Gross Margin-99.11%
Net Profit Margin-144.16%
Debt/Equity Ratio0%

How did MRUS perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is MRUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MRUS?

Other financial metrics that can be useful for relative valuation.

MRUS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11.1x
Enterprise Value/EBITDA-6.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MRUS's PS Ratio compare to its peers?

MRUS PS Ratio vs Peers
The above table shows the PS ratio for MRUS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average26.7x

Price-To-Sales vs Peers: MRUS is good value based on its Price-To-Sales Ratio (18.3x) compared to the peer average (26.7x).


Price to Earnings Ratio vs Industry

How does MRUS's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Sales vs Industry: MRUS is expensive based on its Price-To-Sales Ratio (18.3x) compared to the US Biotechs industry average (14.1x)


Price to Sales Ratio vs Fair Ratio

What is MRUS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MRUS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio18.3x
Fair PS Ratio3.4x

Price-To-Sales vs Fair Ratio: MRUS is expensive based on its Price-To-Sales Ratio (18.3x) compared to the estimated Fair Price-To-Sales Ratio (3.4x).


Share Price vs Fair Value

What is the Fair Price of MRUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MRUS ($22.08) is trading below our estimate of fair value ($141.94)

Significantly Below Fair Value: MRUS is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MRUS's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Merus forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


7.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRUS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MRUS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MRUS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MRUS's revenue (51.6% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: MRUS's revenue (51.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MRUS is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Merus performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-4.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MRUS is currently unprofitable.

Growing Profit Margin: MRUS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MRUS is unprofitable, and losses have increased over the past 5 years at a rate of 4.1% per year.

Accelerating Growth: Unable to compare MRUS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MRUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: MRUS has a negative Return on Equity (-25.4%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Merus's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MRUS's short term assets ($379.7M) exceed its short term liabilities ($61.5M).

Long Term Liabilities: MRUS's short term assets ($379.7M) exceed its long term liabilities ($58.5M).


Debt to Equity History and Analysis

Debt Level: MRUS is debt free.

Reducing Debt: MRUS had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MRUS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MRUS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Merus's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MRUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MRUS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MRUS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MRUS's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MRUS has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Bill Lundberg (58 yo)

2.5yrs

Tenure

US$7,540,935

Compensation

Dr. Sven Ante Lundberg, also known as Bill, M.D., serves as Chief Executive Officer, President and Principal Financial Officer of Merus N.V. since December 31, 2019 and has been its Director since June 201...


CEO Compensation Analysis

Compensation vs Market: Bill's total compensation ($USD7.54M) is above average for companies of similar size in the US market ($USD4.05M).

Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MRUS's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: MRUS's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.6%.


Top Shareholders

Company Information

Merus N.V.'s employee growth, exchange listings and data sources


Key Information

  • Name: Merus N.V.
  • Ticker: MRUS
  • Exchange: NasdaqGM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$961.585m
  • Shares outstanding: 43.55m
  • Website: https://www.merus.nl

Number of Employees


Location

  • Merus N.V.
  • Yalelaan 62
  • Utrecht
  • Utrecht
  • 3584 CM
  • Netherlands

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.